Exabis Library
Welcome to the e-CCO Library!
P689: Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P690: Ambient air quality does not affect disease course in inflammatory bowel disease – a population based risk factor analysis using geographic information systems
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P690: Changes of intestinal microbiota in patients with inflammatory bowel diseases
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P690: Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P690: Rates of IBD in New Zealand Māori population at Lakes District Health Board: low but increasing
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P691: Disparate care: rates of treat to target among patients with inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P691: Influence of ethnicity on the phenotype and clinical outcomes in Inflammatory Bowel Disease; comparison of a South American with a North American population.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P691: UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P692: Clinical, therapeutic and evolutionary profile of fistulizing ano-perineal lesions in Crohn's disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic review
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P692: Inflammatory bowel diseases in Faroese-born Danish residents and their offspring. Further evidence of the dominant role of environmental factors in IBD development
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM